MURA
Mural Oncology plc2.0400
+2.0400+0%
Dec 4, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
35.38MP/E (TTM)
-Basic EPS (TTM)
-6.93Dividend Yield
-Recent Filings
8-K
Acquisition completes at $2.035/share
Mural Oncology's acquisition by XOMA Royalty's subsidiary closed December 5, 2025, after Irish High Court sanction, handing shareholders $2.035 per share in cash. Trading halted on Nasdaq; XOMA took full control, installing Owen Hughes as CEO while prior directors and officers exited with severance. Shareholders lost all rights beyond payout.
10-Q
Q3 FY2025 results
Mural Oncology posted a Q3 operating loss of $4.0M, far better than $34.1M a year earlier (derived), thanks to a $4.8M R&D credit from final ARTISTRY-6 trial reconciliation and post-restructuring cuts. Cash burned to $58.9M from $115.5M year-start, with nine-month operating cash use at $86.6M. No debt; $3.5M lease liability remains. Shareholders approved pending acquisition by XOMA Royalty (announced Aug 2025, base $2.035/share plus up to $0.205 contingent), expected Q4 close. Acquisition failure risks dissolution.
8-K
Shareholders greenlight Mural acquisition
Mural Oncology shareholders overwhelmingly approved the scheme of arrangement on October 24, 2025, paving the way for XOMA Royalty's acquisition via its subsidiary. With over 99% support at both the Scheme Meeting and EGM, the deal advances under Irish law. Closing is targeted for Q4 2025, pending High Court sanction and customary conditions. Yet risks linger if approvals falter.
8-K
Mural Oncology acquisition announced
Mural Oncology agreed to a $2.035 base cash acquisition by XOMA Royalty's subsidiary on August 20, 2025, with potential upside to $2.24 per share if closing net cash exceeds $36.2 million estimates. This follows a strategic review after halting nemvaleukin development, valuing the firm at ~$36.2 million and offering a 13.1% premium to the prior close. Post-close, XOMA plans an orderly wind-down of operations. Shareholder approval and court sanction remain key hurdles.
8-K
Mural's Q2 loss widens amid cuts
Mural Oncology reported Q2 2025 net loss of $48.0 million, up from $31.6 million last year, driven by $17.5 million in restructuring charges after slashing its workforce by 90% and halting all R&D on nemvaleukin alfa and other programs. Cash stood at $77.1 million as of June 30, with estimates of $43-48 million by year-end absent a strategic deal. The company persists in seeking alternatives to maximize shareholder value. No transaction is assured.
IPO
Employees
Sector
Industry
AURA
Aura Biosciences, Inc.
6.18-0.15
CPMV
Mosaic ImmunoEngineering Inc.
0.40+0.00
IMRX
Immuneering Corporation
5.74-0.04
KURA
Kura Oncology, Inc.
10.63+0.07
MAIA
MAIA Biotechnology, Inc.
1.23-0.12
MREO
Mereo BioPharma Group plc
2.10-0.09
MRKR
Marker Therapeutics, Inc.
1.27-0.12
NXTC
NextCure, Inc.
11.12-0.35
OKUR
OnKure Therapeutics, Inc.
3.02-0.18
ZURA
Zura Bio Limited
4.12+0.05